KYNOSELEN - MUSCULAR STIMULANT FOR HORSES AND DOGS

Krajina: Austrália

Jazyk: angličtina

Zdroj: APVMA (Australian Pesticides and Veterinary Medicines Authority)

Kúpte ho teraz

Príbalový leták Príbalový leták (PIL)
19-06-2017

Aktívna zložka:

POTASSIUM ASPARTATE; MAGNESIUM ASPARTATE; HEPTAMINOL HYDROCHLORIDE; SODIUM SELENITE; DISODIC ADENOSINE MONOPHOSPHATE; VITAMIN B12 = CYANOCOBALAMIN

Dostupné z:

Vetoquinol Australia Pty Ltd

INN (Medzinárodný Name):

heptaminol HCl(5g/L)+disodium adenosine monophosp(2g/L) + others

Forma lieku:

PARENTERAL LIQUID/SOLUTION/SUSPENSION

Zloženie:

POTASSIUM ASPARTATE AMINO ACID-ASPARTATE Active 1.0 g/100ml; MAGNESIUM ASPARTATE AMINO ACID-ASPARTATE Active 1.5 g/100ml; HEPTAMINOL HYDROCHLORIDE AMINE/AMIDE Active 0.5 g/100ml; SODIUM SELENITE MINERAL-SELENIUM Active 0.05 g/100ml; DISODIC ADENOSINE MONOPHOSPHATE NUCLEOTIDE Active 0.2 g/100ml; VITAMIN B12 = CYANOCOBALAMIN VITAMIN-B12 Active 0.025 g/100ml

Počet v balení:

100mL

Trieda:

VM - Veterinary Medicine

Terapeutické skupiny:

DOG | HORSE | BITCH | CASTRATE | COLT | DONKEY | ENDURANCE HORSE | FILLY | FOAL | GELDING | HIGH PERFORMANCE HORSES | HORSES AT

Terapeutické oblasti:

NUTRITION & METABOLISM

Terapeutické indikácie:

MUSCULAR DYSTROPHY | MUSCULAR STIMULANT | TYING-UP SYNDROME (HORSES)

Prehľad produktov:

Poison schedule: 6; Withholding period: WHP:Meat- Nil; Host/pest details: DOG: [MUSCULAR DYSTROPHY]; HORSE: [MUSCULAR DYSTROPHY]; Poison schedule: 6; Withholding period: ; Host/pest details: DOG: [MUSCULAR DYSTROPHY]; HORSE: [MUSCULAR DYSTROPHY]; An aid in the control of muscular dystrophy in horses and dogs (tying up syndrome in horses).

Stav Autorizácia:

Stopped

Dátum Autorizácia:

2020-07-01

Príbalový leták

                                Kynoselen - Muscular stimulant for horses and dogs draft label
41608/0901 100mL vial and box
page 1 of 4
May
2016
_Vial main panel _
POISON
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY
Kynoselen
®
- Muscular stimulant for horses and dogs
ACTIVE CONSTITUENTS (per 100mL):
HEPTAMINOL HYDROCHLORIDE
0.50g
DISODIC ADENOSINE MONOPHOSPHATE 0.20g
0.05g
1.50g
1.00g
SODIUM SE
LENITE
MAGNESIUM AS
PARTATE
POTASSIUM ASPARTATE
CYANOCOBALAMIN
0.025g
Intramuscular or Subcutaneous Injectable Solution
An aid in the control of muscular dystrophy in horses and dogs
(tying-up syndrome in horses)
100mL
APPROVED NON-RLP
AMENDMENT MADE
Kynoselen - Muscular stimulant for horses and dogs draft label
41608/0901 100mL vial and box
page 2 of 4
May 2016
_Vial ancillary panel 1 _
DIRECTIONS FOR USE
Treatment: 1 injection once every 3 days for 9 to 12 days.
Prevention:
1 injection once a week for 2 to 3 weeks.
Horses: Adult 20mL.
Foals: 10mL
Dogs:
2 to 5mL according to size by subcutaneous or intramuscular route.
If used in performance animals, the regulations of the relevant
authorities
regarding medication should be observed.
MEAT WITHHOLDING PERIOD: NIL
_Vial ancillary panel 2 _
Manufactured by:
Vétoquinol S.A.
70204 LURE Cedex (France)
Distributed by:
_ _
VETOQUINOL AUSTRALIA Pty Ltd
ABN
64 006 949 480
Unit 302.
2
, 6-12 Boronia Road, Da Vinci Business Park, Brisbane Airport, Qld,
4008
Tel
: 1800 035 355
Email
: sales.australia@vetoquinol.com
Store below 25°C (Air conditioning). Protect from light.
Dispose of empty container by wrapping with paper and putting in
garbage.
NRA Approval No. 41608/0901
Batch:
Expiry:
[packaging ID]
Kynoselen - Muscular stimulant for horses and dogs draft label
41608/0901 100mL vial and box
page 3 of 4
May 2016
_Box main panel _
POISON
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY
Kynoselen
®
- Muscular stimulant for horses and dogs
ACTIVE CONSTITUENTS (per 100mL):
HEPTAMINOL HYDROCHLORIDE
0.50g
DISODIC ADENOSINE MONOPHOSPHATE 0.20g
0.05g
1.50g
1.00g
SODIUM SE
LENITE
MAGNESIUM AS
PARTATE

                                
                                Prečítajte si celý dokument
                                
                            

Súhrn charakteristických

                                PRODUCT NAME: KYNOSELEN® MUSCULAR STIMULANT FOR HORSES AND DOGS
PAGE: 1 OF 4
THIS REVISION ISSUED: OCTOBER, 2008
MATERIAL SAFETY DATA SHEET
ISSUED BY: AUSRICHTER PTY LTD
PHONE: 02 9517 1166
POISONS INFORMATION CENTRE: 13 1126 FROM ANYWHERE IN AUSTRALIA, (0800
764 766 IN NEW ZEALAND)
SECTION 1 - IDENTIFICATION OF CHEMICAL PRODUCT AND COMPANY
AUSRICHTER PTY LTD
PHONE: 02 9517 1166
2/21 CHESTER ST
FAX: 02 9516 5810
CAMPERDOWN NSW 2050
AUSRICHTER@BIGPOND.COM
SUBSTANCE:
Blend of ingredients in water solution; presented as an injectable
solution.
TRADE NAME:
KYNOSELEN
® MUSCULAR STIMULANT FOR HORSES AND DOGS
PRODUCT USE:
An aid in the control of muscular dystrophy in horses and dogs
(tying-up syndrome in
horses) for use as described on the product label.
CREATION DATE:
OCTOBER, 2008
REVISION DATE:
OCTOBER, 2008
SECTION 2 - HAZARDS IDENTIFICATION
STATEMENT OF HAZARDOUS NATURE
This product is classified as:
Not classified as hazardous according to the criteria of ASCC.
Not a Dangerous Good according to the Australian Dangerous Goods (ADG)
Code.
RISK PHRASES:
R33. Danger of cumulative effects.
SAFETY PHRASES:
S24/25. Avoid contact with skin and eyes.
SUSDP CLASSIFICATION:
S6
ADG CLASSIFICATION:
None allocated. Not a Dangerous Good under the ADG Code.
UN NUMBER:
None allocated
EMERGENCY OVERVIEW
PHYSICAL DESCRIPTION & COLOUR
: Red liquid.
ODOUR:
Slight alcohol-like odour.
MAJOR HEALTH HAZARDS:
danger of cumulative effects.
POTENTIAL HEALTH EFFECTS
On injection, heptaminol has an adrenalin-like action in horses. 20g
heptaminol is equivalent to the action produced
by 0.5mg adrenalin.
INHALATION:
SHORT TERM EXPOSURE:
Significant inhalation exposure is considered to be unlikely.
Available data indicates that
this product is not harmful. In addition product is unlikely to cause
any discomfort or irritation.
LONG TERM EXPOSURE:
No data for health effects associated with long term inhalation.
SKIN CONTACT:
SHORT TERM EXPOSURE:
Available data indicates that this product is not harmful. It should
present no hazards in
normal use.
                                
                                Prečítajte si celý dokument